Imricor Medical Systems Inc (ASX: IMR) - Share Price
Current share price for IMR : $1.785 0.065 (3.51%)+
Imricor Medical Systems, Inc. (IMR), an ASX-listed company, is a Company that is engaged in design, manufacture and sell MRI-compatible products for cardiac catheter ablation procedures to treat arrhythmias.
IMR General Information +
| ASX Code | IMR |
| Website | http://imricor.com |
| Industry/Sector | Health Care Equipment |
| Market Cap ($M) | 630 |
| IMR Share Price | $1.785 |
| Day High | $1.870 |
| Day Low | $1.785 |
| Last Close | $1.850 |
| IMR Share Price Movement | $0.07 ( 3.51% ) |
Prices as at 16:40, 25 Jun 2026
+Security prices are delayed by at least 20 minutes and are indicative only.
Imricor Medical Systems Inc (IMR) Upcoming Dividends & Yields
| Distribution Type | Dividend | Franking | Ex-dividend date | Payment date | Current Price+ | Price 7D Avg | Dividend Yield |
|---|
See all dividends from Imricor Medical Systems Inc (IMR) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
Imricor Medical Systems Inc (IMR) price-sensitive announcements
IMR - Submission of the Third PMA Module to the US FDA for Review
Imricor Medical Systems Inc has announced the submission of the third module of its Premar
Imricor Medical Systems Inc (IMR)
11 Jun 2026 | 8:55 AM
11 Jun 2026 | 8:55 AM
IMR - Imricor Completes Successful A$60 Million Capital Raise
Imricor Medical Systems, Inc. announced a successful capital raise of A$60 million through
Imricor Medical Systems Inc (IMR)
4 May 2026 | 9:12 AM
4 May 2026 | 9:12 AM
IMR - Trading Halt
On 30 April 2026, Imricor Medical Systems Inc. (ASX: IMR) requested a trading halt on the
Imricor Medical Systems Inc (IMR)
30 Apr 2026 | 9:59 AM
30 Apr 2026 | 9:59 AM
IMR - Pause in Trading
On 30 April 2026, an ASX Market Release announced a temporary pause in trading for Imricor
Imricor Medical Systems Inc (IMR)
30 Apr 2026 | 9:51 AM
30 Apr 2026 | 9:51 AM
Imricor Medical Systems Inc (IMR) Recent ASX Announcements
IMR Financial Summary
| Year to Dec | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
|---|---|---|---|---|---|---|---|
| 2027F | C2 | -$9.90 | 16.60% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2026F | C2 | -$8.50 | -30.70% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2025A | -$37.83 | -$12.30 | -42.50% | 0.00 | 0.00 | 0.00% | 0.0% |
IMR Peer Comparison
| Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 A | 2026 F | 2027 F | 2025 A | 2026 F | 2027 F | 2025 A | 2026 F | 2027 F | ||
| Cochlear Limited (COH) | $7,420M | 0.0171 | -0.1883 | 0.0862 | 18.9579 | 23.3556 | 21.5030 | 3.79% | 3.06% | 3.26% |
| Fisher & Paykel Healthcare Corporation Limited (FPH) | $17,901M | 0.1388 | 0.1359 | 0.1882 | 46.0910 | 40.5751 | 34.1474 | 1.42% | 1.52% | 1.72% |
| Imricor Medical Systems Inc (IMR) | $654M | -0.4254 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| ResMed Inc. (RMD) | $15,953M | 0.3087 | 9.7634 | 0.0805 | 192.0908 | 17.8466 | 16.5169 | 1.20% | 1.26% | 1.33% |
IMR Market Comparison
| Earnings | P/E Ratio | P/B Ratio | P/E Growth | |
|---|---|---|---|---|
| Company | 0.00 | 0.00 | 33.30 | 0.00 |
| Market | 0.29 | 13.30 | 1.15 | 0.61 |
| Sector | 0.65 | 21.40 | 1.62 | 2.85 |
IMR Directors
| Name | Position | Start Date |
|---|---|---|
| Mr Steve Wedan | Chief Executive Officer, President, Executive Chairman, Executive Director | 23 May 2006 |
| Mr Mark Tibbles | Non-Executive Deputy Chairman, Non-Executive Director | 3 Sep 2014 |
| Mr Peter McGregor | Non-Executive Director | 17 May 2019 |
| Ms Anita Messal | Non-Executive Director | 1 Mar 2021 |
| Mr Jeffrey Leighton | Non-Executive Director | 31 Jul 2024 |
| Mr Aldo Denti | Non-Executive Director | 6 Nov 2025 |
Imricor Medical Systems Inc (IMR) Changes in Directors' Interest & Trades
| Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
|---|---|---|---|---|---|---|
| 5 Jun 2025 | TIBBLES, Mark | Transfer | Direct Shares | 73,380 | $1.090 | $80,000.000 |
| 5 Jun 2025 | TIBBLES, Mark | Sell | Direct Shares | 170,000 | $1.684 | $286,360.000 |
| 22 May 2024 | WEDAN, Steve | Buy | Indirect Shares | 100,000 | $0.450 | $45,000.000 |
See all changes in directors' interest & trades for Imricor Medical Systems Inc (IMR) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
IMR Management
| Name | Position |
|---|---|
| Zheng(Kobe) Li | Company Secretary |
| Kate Lindborg | Vice President of Clinical Affairs |
| Nick Corkill | Vice President of Corporate Strategy |
| Jonathon Gut | Vice President of Finance and Chief Financial Officer |
| Greg Englehardt | Vice President of Global Sales |
| Nick Twohy | Vice President of Marketing and Business Development |
| Vic Fabano | Vice President of Operations |
| Jennifer Weisz | Vice President of Regulatory and Quality |
| Gregg Stenzel | Vice President of Research and Development |
IMR Substantial Shareholders
Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Imricor Medical Systems Inc (IMR). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.
| Holding | Name |
|---|---|
| 19,378,198 (6.04%) | Hart Capital Partners |
| 18,462,138 (5.75%) | Greencape Capital Pty Ltd |
IMR Calendar of Events
| Date | Event |
|---|---|
| 26 March 2027 | Report (Annual) |
| 24 February 2027 | Report (Prelim) |
| 25 August 2026 | Report (Interim) |
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.
What our members say about us
Proudly
We're here to help
Call 1300 880 160
Start a chat
Schedule a call
